News Release
More-
July 16, 2024
Results of a Japan Phase III Clinical Trial of the GnRH Antagonist Linzagolix in Patients with Uterine Fibroids - Primary Endpoint has been Achieved - -
June 10, 2024
Licensing Agreement for GnRH Antagonist Linzagolix with JW Pharmaceutical Corporation in Korea -
March 19, 2024
Notice Concerning Status of Acquisition and Completion of the Company's Own Shares -
March 1, 2024
Notice Concerning Status of Acquisition of the Company's Own Shares -
February 1, 2024
Notice Concerning Status of Acquisition of the Company's Own Shares
Topics
More-
June 28, 2024
Status of Dialogue with Shareholders and Investors (June 28, 2024) -
May 7, 2024
Financial Results (May 7, 2024) -
May 7, 2024
R&D Pipeline as of May 2024 -
January 30, 2024
The Third Quarter of FY2023 (January 30, 2024) -
November 6, 2023
The Second Quarter of FY2023 (November 6, 2023)